Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A time and motion study in eight countries

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  de Cock, Erwin ^a   Kritikou, Persefoni ^b   Sandoval, Mariana ^c   Tao, Sunning ^c   Wiesner, Christof ^d   Carella, Angelo Michele ^e   Ngoh, Charles ^f   Waterboer, Tim ^f,g  

^a United BioSource Corporation   (Spain)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c UNITED BIOSOURCE CORPORATION   (Canada)

^d GENENTECH INC   (United States)

^e IRCSS AOU   (Italy)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; RITUXIMAB;

CLINICAL TRIAL; COMPARATIVE STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA, NON-HODGKIN; MULTICENTER STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TASK PERFORMANCE; TIME FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LYMPHOMA, NON-HODGKIN; RITUXIMAB; TIME AND MOTION STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85019074051     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157957     Document Type: Article

References (20)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013; 49:1374-1403. doi: 10.1016/j.ejca.2012.12.027 PMID: 23485231
2. SEER (Surveillance, Epidemiology and End Results Program): Stat Fact Sheets: Non-Hodgkin Lymphoma. 2015. Available: http://seer.cancer.gov/statfacts/html/nhl.html.
3. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol. 2007; 67(Suppl.):5-14.
4. European Medicines Agency: MabThera. 2009. Available: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000165/human_med_000897.jsp&mid= WC0b01ac058001d124.
5. Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract. 1998; 6:195-197. PMID: 9652253
6. Sonet A, Bolsy A. Rituximab and chemotherapy in diffuse large B-cell lymphoma. Expert Rev Anticancer Ther. 2009; 9:719-726. doi: 10.1586/era.09.30 PMID: 19496708
7. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs. 2007; 67:333-350. PMID: 17335294
8. Data on File F. Hoffmann-La Roche Ltd.
9. Salar A, Bouabdallah R, McIntyre C, Sayyed P, Bittner B. A two-stage Phase Ib study to investigate the pharmacokinetics, safety and tolerability of subcutaneous rituximab in patients with follicular lymphoma as part of maintenance treatment. Blood. 2010; 116:Abstract 2858.
10. Salar A, Bittner S, Bouabdallah R, Brewster M, Catalani O, Follows G, et al. A comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase Ib study. J Clin Oncol. 2014; 32:1782-1791. doi: 10.1200/JCO. 2013.52.2631 PMID: 24821885
11. Davies A, Merli F, Mihaljevic B, Siritanaratkul N, Solal-Céligny P, Barrett M, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2014; 15:343-352. doi: 10.1016/S1470-2045(14)70005-1 PMID: 24521993
12. Tobinai K. Subcutaneous rituximab: a practical approach? Lancet. 2014; 15(3):254-255. doi: 10.1016/ S1470-2045(14)70009-9 PMID: 24521992
13. De Cock E, Pivot X, Hauser N, et al. A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer. Cancer Med 2016:389-397. doi: 10.1002/ cam4.573 PMID: 26806010
14. Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014; 17:459-468. doi: 10. 3111/13696998.2014.914033 PMID: 24720836
15. 1): a UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER-2 positive early breast cancer. Adv Breast Cancer Res. 2013; 2:133-140.
16. Rule S, Briones J, Carella AM, Casasnovas O, Barreto WG, Pocock C, et al. A randomized comparison of maintenance therapy with subcutaneous rituximab for 2 years versus until progression in patients with indolent non-Hodgkin's lymphoma: interim safety data from the MABCUTE study. Blood. 2013; 122:Abstract 3052.
17. Bittner B, Richter WF, Hourcade-Potelleret F, Herting F, Schmidt J. Non-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab. Drug Res (Stuttg). In press.
18. Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, et al. PrefHer Study Group: Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013; 14:962-970. doi: 10. 1016/S1470-2045(13)70383-8 PMID: 23965225
19. Rummel M, Kim TM, Plenteda C, Capochiani E, Mendoza M, Smith R, et al. Patient preference for subcutaneous or intravenous administration of rituximab in previously untreated CD20+ non-Hodgkin lymphoma: interim data from the PrefMab study. Haematologica (EHA annual congress abstracts). 2014; 99:Poster 467.
20. McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects. J Clin Epidemiol. 2014; 67:267-277. doi: 10.1016/j. jclinepi.2013.08.015 PMID: 24275499